5-乙酰氨基-2-羟基-3-硝基苯乙酮 | 70978-41-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-乙酰氨基-2-羟基-3-硝基苯乙酮
• 英文名称: 5-acetamido-2-hydroxy-3-nitroacetophenone
• 英文别名: 3'-Acetyl-4'-hydroxy-5'-nitroacetoanilide；N-(3-acetyl-4-hydroxy-5-nitrophenyl)acetamide
• CAS: 70978-41-5
• 化学式: C₁₀H₁₀N₂O₅
• 分子量: 238.2
• InChiKey: LUSCJQUQAZJVSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-乙酰氨基-2-羟基-3-硝基苯乙酮 在 硫酸 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 2.67h， 生成 2-羟基-3-硝基苯乙酮
  参考文献：
  名称：

  Synthesis and Biochemical Evaluation of a Series of Aminoflavones as Potential Inhibitors of Protein-Tyrosine Kinases p56lck, EGFr, and p60v-src

  摘要：

  A series of nitroflavones, 8a-p, and their corresponding aminoflavone hydrochloride salts, 10a-p, was synthesized. The preparation of nitroflavones 8b-i,o,p began with commercially available o-hydroxyacetophenones 2b-f which were converted to o-hydroxynitroacetophenones 3a-h via a variety of nitration methods, followed by condensation with nitrobenzoyl chlorides and cyclization under acidic condition. The nitroflavones 8aj-n were prepared by nitration of the corresponding flavones 7a-e. These new compounds were evaluated for their abilities to inhibit the in. vitro protein-tyrosine kinase activities of p56(1ck), EGFr, and p60(v-src), and all of the active compounds were amino-substituted flavones. None of the nitroflavones inhibited the enzymes. The most active substance in this series against p56(lck) was compound 10j, which had an IC50 of is mu M. When tested versus EGFr, compounds 10a,m displayed IC50's of 8.7 and 7.8 mu M, respectively. Against p60(v-src), 10a,m showed IC50 values of 28.8 and 38.4 mu M, respectively.

  DOI：

  10.1021/jm00046a020
• 作为产物：
  描述：

  5-氨基-2-羟基苯乙酮 在 硝酸 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 2.33h， 生成 5-乙酰氨基-2-羟基-3-硝基苯乙酮
  参考文献：
  名称：

  Synthesis and Biochemical Evaluation of a Series of Aminoflavones as Potential Inhibitors of Protein-Tyrosine Kinases p56lck, EGFr, and p60v-src

  摘要：

  A series of nitroflavones, 8a-p, and their corresponding aminoflavone hydrochloride salts, 10a-p, was synthesized. The preparation of nitroflavones 8b-i,o,p began with commercially available o-hydroxyacetophenones 2b-f which were converted to o-hydroxynitroacetophenones 3a-h via a variety of nitration methods, followed by condensation with nitrobenzoyl chlorides and cyclization under acidic condition. The nitroflavones 8aj-n were prepared by nitration of the corresponding flavones 7a-e. These new compounds were evaluated for their abilities to inhibit the in. vitro protein-tyrosine kinase activities of p56(1ck), EGFr, and p60(v-src), and all of the active compounds were amino-substituted flavones. None of the nitroflavones inhibited the enzymes. The most active substance in this series against p56(lck) was compound 10j, which had an IC50 of is mu M. When tested versus EGFr, compounds 10a,m displayed IC50's of 8.7 and 7.8 mu M, respectively. Against p60(v-src), 10a,m showed IC50 values of 28.8 and 38.4 mu M, respectively.

  DOI：

  10.1021/jm00046a020

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À LA SUBSTANCE AMYLOÏDE
  申请人：REMYND NV

  公开号：WO2016083490A1

  公开（公告）日：2016-06-02

  This invention provides novel compounds of formulae (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein the substituents are as defined in the specification. The present invention also relates to the novel compounds for use as a medicine, more in particular for the prevention or treatment of amyloid-related diseases, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such amyloid-related diseases. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  这项发明提供了式(I)或(II)或其立体异构体、对映异构体、消旋体或互变异构体的新化合物，其中取代基如规范中所定义。本发明还涉及用作药物的这些新化合物，更具体地用于预防或治疗与淀粉样蛋白相关的疾病，更具体地说是某些神经系统疾病，如被统称为tau病变的疾病，以及由细胞毒性α-突触核蛋白淀粉生成所特征化的疾病。本发明还涉及利用这些新化合物制备对治疗此类淀粉样蛋白相关疾病有用的药物。本发明还涉及包括这些新化合物的药物组合物以及这些新化合物的制备方法。
• Cdk inhibitors having 3-hydroxychromen-4-one structure
  申请人：——

  公开号：US20030125356A1

  公开（公告）日：2003-07-03

  The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.

  本发明涉及一种新型的3-羟基香豆素-4-酮衍生物，其化学式为(1)，以及其在药理学上可接受的盐、水合物、溶剂合物或同分异构体，该衍生物可用作 Cyclin Dependent Kinase (“CDK”) 的抑制剂；还涉及制备化合物(1)的方法；以及一种用于抑制或治疗癌症和由细胞增殖引起的疾病，如炎症、血管狭窄、血管生成等的组合物，该组合物以化合物(1)作为活性成分，与药理学上可接受的载体一起使用。
• N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof
  申请人：Antel Jochen

  公开号：US20070117823A1

  公开（公告）日：2007-05-24

  N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.

  式I的N-磺胺基-N'-苯并吡啶啉化合物及其生理上可接受的酸盐，包含它们的药物组合物，其制备方法，以及它们用于治疗和/或抑制青光眼、癫痫、双相情感障碍、偏头痛、神经痛、肥胖症、2型糖尿病、代谢综合征、酒精依赖症和/或癌症的用途，以及相关的并发和/或继发疾病或症状。
• WO2007/54580
  申请人：——

  公开号：——

  公开（公告）日：——
• Kasahara, Nippon Kagaku Zasshi, 1958, vol. 79, p. 335,337
  作者：Kasahara

  DOI：——

  日期：——

表征谱图